Nadine Van Roy

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7298920/publications.pdf

Version: 2024-02-01

		236925	155660
65	3,337	25	55
papers	citations	h-index	g-index

69	69	69	4673
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Exhaustive mutation analysis of theNF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Human Mutation, 2000, 15, 541-555.	2.5	477
2	Gain of Chromosome Arm 17q and Adverse Outcome in Patients with Neuroblastoma. New England Journal of Medicine, 1999, 340, 1954-1961.	27.0	456
3	Genome dynamics of the human embryonic kidney 293 lineage in response to cell biology manipulations. Nature Communications, 2014, 5, 4767.	12.8	421
4	Meta-analysis of Neuroblastomas Reveals a Skewed ALK Mutation Spectrum in Tumors with MYCN Amplification. Clinical Cancer Research, 2010, 16, 4353-4362.	7.0	243
5	Unequivocal Delineation of Clinicogenetic Subgroups and Development of a New Model for Improved Outcome Prediction in Neuroblastoma. Journal of Clinical Oncology, 2005, 23, 2280-2299.	1.6	160
6	Genetic heterogeneity of neuroblastoma studied by comparative genomic hybridization. Genes Chromosomes and Cancer, 1998, 23, 141-152.	2.8	121
7	Molecular cytogenetic and clinical findings inETV6/ABL1-positive leukemia. Genes Chromosomes and Cancer, 2001, 30, 274-282.	2.8	103
8	Multicentre analysis of patterns of DNA gains and losses in 204 neuroblastoma tumors: How many genetic subgroups are there?. Medical and Pediatric Oncology, 2001, 36, 5-10.	1.0	82
9	Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment. Clinical Cancer Research, 2015, 21, 3327-3339.	7.0	76
10	ZEB2 drives immature T-cell lymphoblastic leukaemia development via enhanced tumour-initiating potential and IL-7 receptor signalling. Nature Communications, 2015, 6, 5794.	12.8	75
11	Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international study. Blood, 2015, 126, 1575-1584.	1.4	69
12	ArrayCGHâ€based classification of neuroblastoma into genomic subgroups. Genes Chromosomes and Cancer, 2007, 46, 1098-1108.	2.8	67
13	Pallister-killian syndrome: Characterization of the isochromosome 12p by fluorescentIn Situ hybridization. American Journal of Medical Genetics Part A, 1991, 41, 381-387.	2.4	65
14	Frequent allelic loss at 10q23 but low incidence ofPTEN mutations in merkel cell carcinoma. International Journal of Cancer, 2001, 92, 409-413.	5.1	63
15	The pitfalls and promise of liquid biopsies for diagnosing and treating solid tumors in children: a review. European Journal of Pediatrics, 2020, 179, 191-202.	2.7	55
16	Tandem repeats of Allium fistulosum associated with major chromosomal landmarks. Molecular Genetics and Genomics, 2017, 292, 453-464.	2.1	52
17	Translocationâ€“excisionâ€“deletionâ€“amplification mechanism leading to nonsyntenic coamplification of MYC and ATBF1. Genes Chromosomes and Cancer, 2006, 45, 107-117.	2.8	47
18	Combined M-FISH and CGH analysis allows comprehensive description of genetic alterations in neuroblastoma cell lines. Genes Chromosomes and Cancer, 2001, 32, 126-135.	2.8	46

#	Article	IF	Citations
19	Identification of two distinct chromosome 12-derived amplification units in neuroblastoma cell line NGP. Cancer Genetics and Cytogenetics, 1995, 82, 151-154.	1.0	43
20	Focal DNA Copy Number Changes in Neuroblastoma Target MYCN Regulated Genes. PLoS ONE, 2013, 8, e52321.	2.5	37
21	Molecular cytogenetic delineation of 17q translocation breakpoints in neuroblastoma cell lines. , 1998, 23, 116-122.		36
22	The emerging molecular pathogenesis of neuroblastoma: implications for improved risk assessment and targeted therapy. Genome Medicine, 2009, 1, 74.	8.2	34
23	Unique long non-coding RNA expression signature in ETV6/RUNX1-driven B-cell precursor acute lymphoblastic leukemia. Oncotarget, 2016, 7, 73769-73780.	1.8	30
24	Structure and mutation analysis of the gene encoding DNA fragmentation factor 40 (caspase-activated) Tj ETQq0 0 0 rgBT /Overlock 10	3.8	28
25	Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma. Blood, 2020, 135, 1685-1695.	1.4	28
26	Anchoring Linkage Groups of the Rosa Genetic Map to Physical Chromosomes with Tyramide-FISH and EST-SNP Markers. PLoS ONE, 2014, 9, e95793.	2.5	27
27	Extrauterine Mesonephric-like Neoplasms. American Journal of Surgical Pathology, 2022, 46, 124-133.	3.7	26
28	Subtelomeric familial translocation t(2;7)(q37;q35) leading to partial trisomy 7q35?qter: Molecular cytogenetic analysis and clinical phenotype in two generations. American Journal of Medical Genetics Part A, 2000, 93, 349-354.	2.4	24
29	Minimally invasive classification of paediatric solid tumours using reduced representation bisulphite sequencing of cell-free DNA: a proof-of-principle study. Epigenetics, 2021, 16, 196-208.	2.7	23
30	Balanced translocation in a neuroblastoma patient disrupts a cluster of small nuclear RNA UI and tRNA genes in chromosomal band Ip36. Genes Chromosomes and Cancer, 1995, 14, 35-42.	2.8	22
31	Identification of 2 putative critical segments of 17q gain in neuroblastoma through integrative genomics. International Journal of Cancer, 2008, 122, 1177-1182.	5.1	22
32	Localization of the 17q breakpoint of a constitutional 1;17 translocation in a patient with neuroblastoma within a 25-kb segment located between theACCN1 andTLK2 genes and near the distal breakpoints of two microdeletions in neurofibromatosis type 1 patients. Genes Chromosomes and Cancer, 2002, 35, 113-120.	2.8	21
33	Towards a FISH-based karyotype of Rosa L. (Rosaceae). Comparative Cytogenetics, 2016, 10, 543-554.	0.8	21
34	Is t(6;20)(p21;q13) a characteristic chromosome change in endometrial polyps?. Genes Chromosomes and Cancer, 1991, 3, 318-319.	2.8	20
35	Molecular basis and clinical significance of genetic aberrations in B-cell precursor acute lymphoblastic leukemia. Experimental Hematology, 2015, 43, 640-653.	0.4	20
36	Monosomy 22 in a mixed germ cell-sex cord-stromal tumor of the ovary. Genes Chromosomes and Cancer, 1997, 19, 192-194.	2.8	18

#	Article	IF	Citations
37	Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma. Haematologica, 2019, 104, e17-e20.	3.5	18
38	Molecular cytogenetic analysis of a complex t(10;22;11) translocation in ewing's sarcoma. Genes Chromosomes and Cancer, 1992, 4, 188-191.	2.8	17
39	Chromosome 2 short arm translocations revealed by M-FISH analysis of neuroblastoma cell lines. Medical and Pediatric Oncology, 2000, 35, 538-540.	1.0	17
40	Cytogenetic and molecular analysis of cellular atypical mesoblastic nephroma. , 1998, 21, 265-269.		16
41	The feasibility of using liquid biopsies as a complementary assay for copy number aberration profiling in routinely collected paediatric cancer patient samples. European Journal of Cancer, 2022, 160, 12-23.	2.8	16
42	Molecular cytogenetic analysis of a familial pericentric inversion of chromosome 12. Clinical Genetics, 1993, 44, 156-163.	2.0	12
43	Association of unbalanced translocation der(1;7) with germline GATA2 mutations. Blood, 2021, 138, 2441-2445.	1.4	12
44	Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group. Journal of Clinical Oncology, 2020, 38, 3685-3697.	1.6	9
45	CD200/BTLA deletions in pediatric precursor B-cell acute lymphoblastic leukemia treated according to the EORTC-CLG 58951 protocol. Haematologica, 2015, 100, 1311-1319.	3.5	8
46	Evidence for involvement of a tumor suppressor gene on 1p in malignant peripheral nerve sheath tumors. Cancer Genetics and Cytogenetics, 2003, 143, 120-124.	1.0	7
47	Detection of Copy Number Alterations by Shallow Whole-Genome Sequencing of Formalin-Fixed, Paraffin-Embedded Tumor Tissue. Archives of Pathology and Laboratory Medicine, 2020, 144, 974-981.	2.5	6
48	Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Human Mutation, 2000, 15, 541.	2.5	6
49	Reciprocal translocation between the proximal regions of the long arms of chromosomes 13 and 15 resulting in unbalanced offspring: characterization by fluorescence in situ hybridization and DNA analysis. Human Genetics, 1992, 89, 407-413.	3.8	5
50	Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. , 2000, 15, 541.		4
51	Malignant pleural mesothelioma with an EML4-ALK fusion: Expect the unexpected!. Pathology Research and Practice, 2022, 231, 153772.	2.3	4
52	Molecular cytogenetic and clinical findings in ETV6ABL1â€positive leukemia. Genes Chromosomes and Cancer, 2001, 30, 274-282.	2.8	3
53	A case of chronic eosinophilic leukemia with secondary transformation to acute myeloid leukemia. Leukemia Research Reports, 2018, 9, 45-47.	0.4	2
54	Development of chronic myeloid leukemia in a patient previously diagnosed with a JAK2-positive myeloproliferative neoplasm. Clinical Chemistry and Laboratory Medicine, 2021, 59, e392-e394.	2.3	2

#	Article	IF	Citations
55	From DNA Copy Number Gains and Tumor Dependencies to Novel Therapeutic Targets for High-Risk Neuroblastoma. Journal of Personalized Medicine, 2021, 11, 1286.	2.5	2
56	Monosomy 22 and partial loss of INI1 expression in a biphasic synovial sarcoma with an Ewing sarcoma-like poorly differentiated component: Report of a case. Pathology Research and Practice, 2016, 212, 658-664.	2.3	1
57	MicroRNA signatures in Genetic Subtypes of T-Cell Acute Lymphoblastic Leukemia.. Blood, 2008, 112, 3360-3360.	1.4	1
58	The challenging differential diagnosis of skin tumours with a rhabdoid phenotype: not all tumours with rhabdoid phenotype belong to the group of <scp>SMARCB</scp>1â€deficient tumours. Histopathology, 2016, 68, 608-612.	2.9	0
59	MicroRNA Profiling of EVI1 Deregulated Myeloid Leukemia.. Blood, 2007, 110, 4146-4146.	1.4	0
60	MicroRNA Profiling of EVI1 Deregulated Myeloid Leukemia. Blood, 2008, 112, 5322-5322.	1.4	0
61	Comparison of miRNA Profiles of Microdissected Hodgkin/Reed-Sternberg Cells and Hodgkin Cell Lines Versus CD77+ B-Cells Reveals a Distinct Subset of Differentially Expressed miRNAs. Blood, 2008, 112, 4488-4488.	1.4	0
62	Improved Detection of Chromosomal Abnormalities in CLL by Conventional Cytogenetics Using CpG Oligonucleotide and Interleukin-2 Stimulation. A Belgian Multicentric Study. Blood, 2008, 112, 3118-3118.	1.4	0
63	Downregulation of MiR-449a Is Essential for the Survival of EVI1 Positive Leukemic Cells through Modulation of NOTCH1 and BCL2.. Blood, 2009, 114, 361-361.	1.4	0
64	Regulatory Networks Governed by MicroRNAs in T-ALL Oncogenesis and Normal T-Cell Development. Blood, 2011, 118, 1366-1366.	1.4	0
65	Prognostic Relevance of CD200/Btla Deletions in Pediatric Precursor-B Cell Acute Lymphoblastic Leukemia Treated According to the EORTC-CLG 58951 Protocol. Blood, 2014, 124, 2394-2394.	1.4	0